Skip to main content
NCBI home page
Frontiers in Cellular and Infection Microbiology logoLink to Frontiers in Cellular and Infection Microbiology
. 2022 Jul 28;12:955847. doi: 10.3389/fcimb.2022.955847

Role of HPV16 E1 in cervical carcinogenesis

Fern Baedyananda 1,2, Thanayod Sasivimolrattana 3,4, Arkom Chaiwongkot 1,4, Shankar Varadarajan 2, Parvapan Bhattarakosol 1,4,*
PMCID: PMC9368317  PMID: 35967849

Abstract

Cervical cancer is the fourth most common cancer in women worldwide. More than 90% of cases are caused by the human papillomavirus (HPV). Vaccines developed only guard against a few HPV types and do not protect people who have already been infected. HPV is a small DNA virus that infects the basal layer of the stratified epithelium of the skin and mucosa through small breaks and replicates as the cells differentiate. The mucosal types of HPV can be classified into low-risk and high-risk groups, based on their association with cancer. Among HPV types in high-risk group, HPV type 16 (HPV-16) is the most common, causing 50% of all cancer cases. HPV infection can occur as transient or persistent infections, based on the ability of immune system to clear the virus. Persistent infection is characterized by the integration of HPV genome. HPV-16 exhibits a different integration pattern, with only 50% reported to be integrated at the carcinoma stage. Replication of the HPV genome depends on protein E1, an ATP-dependent helicase. E1 is essential for the amplification of the viral episome in infected cells. Previous studies have shown that E1 does not only act as a helicase protein but is also involved in recruiting and interacting with other host proteins. E1 has also been deemed to drive host cell proliferation. Recent studies have emphasized the emerging role of HPV E1 in cervical carcinogenesis. In this review, a possible mechanism by which E1 drives cell proliferation and oncogenesis will be discussed.

Keywords: HPV, HPV16, HPV16 E1, cervical carcinogenesis, cervical cancer

Introduction

Cervical cancer (CC) is one of the most frequent common malignancies in women worldwide. Persistent infection with some types of human papillomaviruses (HPVs) is the major factor contributing to the development of cervical carcinogenesis (Schiffman et al., 2007; Petry, 2014). To observe the histological abnormality of the patients, colposcopy with biopsy, endocervical scraping, and cone biopsies are performed. The abnormalities detected in biopsy samples are termed cervical intraepithelial neoplasia (CIN) or dysplasia. These CINs are divided into 3 major stages, i.e., CIN1, CIN2, and CIN3, including carcinoma in situ (Waxman et al., 2012). Moreover, if cancerous cells are observed, they will be identified as squamous cell carcinoma (SCC) or adenocarcinoma.

HPVs are epitheliotropic viruses with an 8 kbp double-stranded circular DNA genome contained in the naked icosahedral capsid. The HPV’s genomic DNA is packaged as a minichromosome with cellular nucleosomal histone (Acheson, 2011). HPV belongs to family Papillomaviridae and currently divided into 5 genera, namely Alpha-, Beta-, Gamma-, Mupa- and Nupapapillomavirus containing members, all of which can infect humans (Brooks et al., 2013). To this date, more than 200 HPV types have been identified (McBride, 2017). In the Alphapapillomavirus genus, HPVs are divided into two major groups - high-risk HPVs (Hr-HPVs) and low-risk HPVs (Lr-HPVs) - based on the cancer risk associated with their infection. Hr-HPVs include types 16, 18, 31 and 33 (Ghittoni et al., 2015), whereas Lr-HPVs include types 6 and11 (Brooks et al., 2013).

Papillomaviruses can infect a wide range of animal species; however, each type of papillomavirus is highly host- and tissue-specific. HPV infects cells in the basal layer of the epithelium, following wounds or breaks in the epithelium. Upon infection, HPVs maintain their genome as an extrachromosomal element, or episome, in the nucleus of infected cells. At this infection stage, and while the cells are in the lower strata of the epithelium, only the early genes are expressed (Graham, 2017). When the infected cell proliferates, the HPV genome replicates and increases the episomal copy numbers in the cell. The viral genome is replicated along with host cell DNA replication; after cell division occurs, the daughter cell contains a copy of the HPV genome. There is no new virion progeny produced in this initial phase. When the cell proliferates and differentiates, HPV DNA replication increases, resulting in a high episomal viral genome copy number (Burd, 2003). Finally, in the upper strata of the epithelium, the late proteins are encoded for capsid formation and released in the upper strata of the epithelium (Longworth and Laimins, 2004). Most HPV infections are transient and are cleared within approximately 2 years; nevertheless, if the host immune system is unable to clear the infection, a persistent infection occurs, possibly leading to viral genome integration into the host cell (Plummer et al., 2007).

The HPV genome encodes about 8 open-reading frames (ORFs), of which are divided into three functional regions - early (E) region, late (L) region, and noncoding part or long control region (LCR) (Yousefi et al., 2021). The early region encodes 6 early proteins (E1, E2, E4, E5, E6, and E7), whereas the late region encodes only 2 structural proteins, L1, and L2, that compose the capsid of HPVs (Chan et al., 2019). Whilst E1 has been shown to encode the primary protein responsible for viral replication (Berg and Stenlund, 1997), E2 is involved in transcriptional regulation (Chojnacki and Melendy, 2018), and E4 regulates virion release (Doorbar et al., 1996). The late proteins L1 and L2 are the major (80%) and minor (20%) capsid proteins, respectively. In contrast to these proteins, the functional roles of E5, E6 and E7 have been extensively characterized in the context of cancer. For instance, HPV E5 plays a role in immune evasion whereas E6 and E7 causes hyper-proliferation of the cell and cancer progression (Crook et al., 1991; Ganguly, 2012). The major role of the HPV E6 oncoprotein is to immortalize the cells via the ubiquitin-dependent proteasome degradation of p53, a cellular tumor suppressor protein, thus evading cancer cell death (Nguyen et al., 2002; Kelley et al., 2005). In addition, E6 can also degrade other apoptotic signaling cascade molecules (Filippova et al., 2002). HPV E7 oncoprotein plays a critical role in cervical carcinogenesis through dysregulation of cell cycle. This protein inactivates the retinoblastoma tumor suppressor protein (pRb) and downregulates E2F (Moody and Laimins, 2010). It is therefore evident that the role of HPV proteins, other than E5, E6, and E7, in carcinogenesis is under-investigated. Recently, it has been shown that HPV E1 may be involved in carcinogenesis. Here, we will review the possible role of E1 in cervical carcinogenesis.

The structure of E1 protein

The E1 protein serves as the primary replication protein of HPV and is an ATP-dependent helicase that binds to the viral origin of replication and unwinds the viral DNA to initiate replication (Hughes and Romanos, 1993). Across all papillomaviruses, the E1 protein is the most conserved, primarily owing to its helicase function, which is essential for the viral episome replication. It is possible that all phases of the viral replication cycle namely, establishment, maintenance, and amplification, require E1 function. The E1 protein consists of three main domains, each with a distinct and important function, i.e., The N-terminal regulatory domain, the DNA binding domain, and the helicase domain (Figure 1A) (Bergvall et al., 2013). The N-terminal of the protein contains the nuclear localization signal and the nuclear export signal, which functions to transport E1 between the nucleus and cytoplasm. The DNA binding domain recognizes specific sequences near the viral origin of replication, which is bound by the helicase domain to form a doughnut shaped complex around viral DNA (Enemark and Joshua-Tor, 2006).

Figure 1.

Figure 1

Open in a new tab

Structure and function of HPV E1. (A) Diagram of the HPV E1 protein domains. Three major functional domains of HPV E1, i.e., N-terminal, DNA binding domain (DBD), and the domain which construct the helicase domain: minimal oligomerization domain, ATPase domain, and C-terminal brace. (B) Schematic representation of the initiation of the HPV DNA replication associated with E1 protein. HPV E1 proteins are recruited to bind to the E1 DNA binding site at the origin by HPV E2. E1 and E2 are assemble as E1-E2-ori ternary complex. Additional of E1 proteins are recruited to assemble as E1 double-trimer and double-hexamer, respectively. Then, the ds-DNA are unwound, and the DNA replication are initiated by the recruitment of host DNA replication factors.

Mechanisms of HPV E1 in viral DNA replication

To initiate HPV DNA replication, E1 interacts with E2 (Berg and Stenlund, 1997; Bergvall et al., 2013; Porter et al., 2017), which aids in its recruitment to the origin of replication (Frattini and Laimins, 1994) (Figure 1B). It must be noted that E1 can also establish viral replication in an E2 independent manner, albeit with lower efficiency (Bonne-Andrea et al., 1997). Upon binding to the origin of replication as an E1-E2-ori ternary complex, additional E1 molecules are recruited to assemble E1 double-trimers and E1 double-hexamers, which whilst unwinding DNA also recruits several DNA replication factors, such as DNA polymerase α primase (Pol α-prim), topoisomerase I (Topo I), and replication protein A (RPA) (Loo and Melendy, 2004; Bergvall et al., 2013).

Relationship between HPV16 E1 expression and cervical cancer progression

The most well-characterized function of HPV in cervical carcinogenesis is the overexpression of E6 and E7 oncoproteins, which mainly target p53 and pRb tumor suppressor proteins (Munger et al., 1992; Mantovani and Banks, 2001). However, a relationship between HPV E1 expression and cervical cancer progression has been reported. Interestingly, HPV16 E1 mRNA expression is positively correlated with cervical cancer progression (Baedyananda et al., 2017). This finding was in agreement with another independent study that reported lower E1 expression in patients with low-grade squamous intraepithelial lesion (LSIL) compared to high-grade squamous intraepithelial lesion (HSIL) and cancer (Schmitt et al., 2011).

The physical state of the HPV genome, namely integrated, episomal, or mixed, is correlated with cervical carcinogenesis (Pirami et al., 1997; Williams et al., 2011). HPV integration is associated with overexpression of E6 and E7 (Jeon et al., 1995), which in turn have been shown to enhance the pathogenicity of HPV (Munger et al., 1992; Burke et al., 2012; Burke et al., 2014). However, recent findings have reported that E1 mRNA expression is neither impacted by the number of copies of the HPV16 genome, nor its physical state (Baedyananda et al., 2017). Similar observations have also been made in relation to E6 and E7 (Wang-Johanning et al., 2002), which implicates other factors, including epigenetic modifications in the control of HPV mRNA expression. Moreover, HPV genome has been reported to be highly methylated in cervical cancer samples with high copy numbers of integrated HPV (Chaiwongkot et al., 2013). In agreement, E1 promoters p97 and p670 are hypermethylated in cervical cancer samples when compared to normal samples (Baedyananda et al., 2017), thereby suggesting the possibility of these samples possessing high numbers of HPV genome copies.

The possible functions of HPV16 E1 in cervical carcinogenesis

HPV16 E1 dysregulates the expression of genes involved in cell survival

Failure to induce apoptosis could drive tumorigenesis through multiple mechanisms (Ichim and Tait, 2016). In HPV16 E1 overexpressing cells, several host genes that are involved in protein synthesis (RPL36A), metabolism (ALDOC), immune response (ISG20), DNA damage (ATR, BRCA1, and CHK1), and cell proliferation (CREB5, HIF1A, NFKB1, PIK3CA, JMJDIC, TSC22D3, FOXO3), have been shown to be significantly downregulated (Baedyananda et al., 2021). Of the transcriptional factors, CREB5, HIF1A, NFKB1, and PIK3CA, downregulation of NFKB1 and PIK3CA supports tumor growth and survival (Xia et al., 2014; Masoud and Li, 2015). JMJD1C (Jumonji Domain Containing 1C) is a histone demethylase, tumor suppressor protein that is usually found to be reduced or lost in breast cancer (Watanabe et al., 2013). TSC22D3 is a gene that encodes Glucocorticoid-induced leucine zipper (GILZ), which in turn activates FOXO3a-mediated transcription of the pro-apoptotic protein, Bim (Joha et al., 2012). Loss of FOXO3a activity has previously been linked to disease progression in carcinogen-induced lung adenocarcinoma (Blake et al., 2010), neck cancer (Shou et al., 2012) and urothelial cancer (Shiota et al., 2010). How HPV16 E1 promotes cell survival via regulation of FOXO3 in cervical carcinogenesis is still unclear.

HPV16 E1 mutations associated with cervical cancer

A variety of mutations in E1/E2 genes have been identified in cervical cancer samples. The clinical stage of patients with the discovered HPV E1 mutations have also been noted in various studies. Many of these variants were linked with lower grade lesions such as noted in previous studies where a 63-bp duplication variant was associated with lower disease progression (Sabol et al., 2008; Baedyananda et al., 2017). Other mutations have demonstrated reduced abilities to support HPV replication (Yao et al., 2019) and also failed to suppress the viral early promoter (Yao et al., 2019; Hirose et al., 2020). When examining within-host variations of HPV16 it was noted that non-synonymous substitutions occurred more frequently in invasive carcinoma specimens. These mutations also occurred more frequently in E1/E2 regions than in other regions of the viral genome (Hirose et al., 2020). Many factors determine the functional impact of mutations i.e., type of mutation, location of the mutation. Further studies are required to understand how information gained from this could be therapeutically exploited.

Helicase function of HPV E1 and possible roles in cancer

Genome instability, a hallmark of cancer (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011), is caused by several factors that induce DNA damage (Langie et al., 2015), which could be exacerbated by defective DNA damage repair response and tumor suppressor molecules (Negrini et al., 2010). Inactivating mutations in DNA helicases have detrimental effects, such as in Werner syndrome, characterized by the appearance of premature aging features and early onset of age-related diseases such as cardiovascular diseases, diabetes mellitus, and carcinoma (Martin, 1985). Patients with Bloom’s syndrome are also predisposed to carcinogenesis (German, 1997). In addition, cells transformed by the Epstein-Barr virus (EBV) and simian virus 40 (SV40) have exhibited upregulated helicases expression. In the context of HPV infection, E1 helicase facilitates HPV genome replication, via the host cells’ DNA damage repair pathways and contributes to carcinogenesis (Moody and Laimins, 2009; King et al., 2010; Fradet-Turcotte et al., 2011; Sakakibara et al., 2011). HPV E1 proteins are able to directly cause double strand DNA breaks in the host genome. The ATR-dependent DNA damage response pathway is activated by HPV replication or presence of HPV replication proteins, E1 and E2. This has been shown by the accumulation of γH2AX, ATR-interacting protein (ATRIP), and topoisomerase IIβ-binding protein 1 (TopBP1) in replication centers. Conversely, the viral oncoproteins E6 and E7 did not play a role in the accumulation of γH2AX, ATRIP and TopBP1 (Reinson et al., 2013).

Moreover, the homeobox transcription factor HOXC13 has been shown to upregulate the expression of HPV16/18 E1 and E2 (Ishii et al., 2020), which may enhance the helicase activity of E1 to result in DNA damage and genome instability. HPV E1’s ability to directly cause host DNA damage and the implications on carcinogenesis should be further explored to better define the role of HPV E1 in carcinogenesis.

Role of HPV16 E1 in antiviral immune evasion

Type I interferons (IFN), such as, IFN-α and IFN-β, form integral components of the innate immune response, playing important roles in antiviral, anti-proliferative and immunomodulatory functions (Seth et al., 2006). HPV18 E1 modulates the expression of the genes involved in toll-like receptor, interferons and apoptosis pathways, and antiviral interferon-stimulated gene set (Castillo et al., 2014). Similarly, HPV16/18 E1 protein has been shown to enhance the expression of immune response genes, i.e., IFNβ1, IFNλ1, and interferon-stimulated gene (ISG) (Castro-Muñoz et al., 2019), thus implicating roles for HPV E1 in immune modulation, as evasion of the host immune response is key to persistent infection and HPV-related carcinogenesis.

Conclusion

Several studies have explored possible roles of HPV16 E1 in cervical carcinogenesis and have attributed numerous cellular mechanisms, including increased expression of genes involved in cell survival and apoptosis, inhibition of the antiviral immune response, viral genome maintenance, helicase activity and inactivating mutations (Figure 2). However, there are no functional evidence of HPV16 E1 directly on cancer development. It is possible that E1 is the only protein with both DNA helicase and ATPase activity, which may or may not be relevant for carcinogenesis. Unfortunately, only few studies worked on HPV16 E1 related to cancer development. For further study, the function of E1 protein in cervical carcinogenesis should be deeply explored. More functional assays related to the hallmarks of cancer, e.g., cell proliferation, apoptosis, cell cycle arrested, migration/invasion, wound healing, and colony formation, should be done in E1 overexpressed/knockdown/knockout cells. Moreover, many genes such as BCL2L1, CSP2, FOXO3a, JMJDIC, and TSC22D3, were dysregulated in either HPV18 or HPV16 E1 overexpressed/knockdown cells (Castillo et al., 2014; Baedyananda et al., 2021). To better understand the E1 associated cellular pathways, the relationship between E1 and those genes as well as E1 protein-protein interaction should be investigated. Since HPV E1 proteins are helicases, studying cells over-expressing HPV16 E1 and observing the impact on genome instability could expand our understanding of the carcinogenic role of HPV16 E1. In addition, the association between the expression of some cellular genes mentioned above and various stage of cervical specimens should be determined to confirm the phenomenon truly occur in human. Taken together, uncovering the cellular and molecular mechanisms underlying HPV16 E1-mediated cervical carcinogenesis is therefore critical to identify novel biomarkers and/or druggable targets and/or a possible forth HPV oncoprotein beside E5, E6 and E7.

Figure 2.

Figure 2

Open in a new tab

Role of HPV E1. Left panel: the well-known helicase function of HPV. Right panel: the possible roles of HPV E1 in cervical carcinogenesis include dysregulating the expression of genes involved in cell survival, E1 mutation, E1 overexpression, inducing DNA damage, viral genome maintenance, and regulating the expression of immune response genes.

Author contributions

Conceptualization, FB, TS, and PB; Writing – Original Draft Preparation, FB, and TS; Writing – Review & Editing, PB, SV, and AC; Supervision, PB; Project Administration, PB and SV; Funding Acquisition, FB, TS, PB, SV and AC; Figure Illustration, TS. All authors contributed to the article and approved the submitted version.

Funding

The 100th Anniversary Chulalongkorn University Fund for Doctoral Scholarship, The Overseas Research Experience Scholarship for Graduate Student, Rachadaphiseksomphot Endowment Fund, and Thailand Science Research and Innovation Fund (TSRI), Chulalongkorn University, Bangkok 10330, Thailand and University of Liverpool, UK.

Acknowledgments

We would like to acknowledge that all figures were created with BioRender.com platform.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  1. Acheson N. H. (2011). Fundamentals of Molecular Virology. (Hoboken, New Jersey), USA: John Wiley & Sons, INC. (John Wiley & Sons, INC; ). [Google Scholar]
  2. Baedyananda F., Chaiwongkot A., Bhattarakosol P. (2017). Elevated HPV16 E1 expression is associated with cervical cancer progression. Intervirology 60 (5), 171–180. doi:  10.1159/000487048 [DOI] [PubMed] [Google Scholar]
  3. Baedyananda F., Chaiwongkot A., Varadarajan S., Bhattarakosol P. (2021). HPV16 E1 dysregulated cellular genes involved in cell proliferation and host DNA damage: A possible role in cervical carcinogenesis. PloS One 16 (12), e0260841. doi:  10.1371/journal.pone.0260841 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Berg M., Stenlund A. (1997). Functional interactions between papillomavirus E1 and E2 proteins. J. Virol. 71 (5), 3853–3863. doi:  10.1128/JVI.71.5.3853-3863.1997 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bergvall M., Melendy T., Archambault J. (2013). The E1 proteins. Virology 445 (1-2), 35–56. doi:  10.1016/j.virol.2013.07.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Blake D. C., Jr., Mikse O. R., Freeman W. M., Herzog C. R. (2010). FOXO3a elicits a pro-apoptotic transcription program and cellular response to human lung carcinogen nicotine-derived nitrosaminoketone (NNK). Lung Cancer 67 (1), 37–47. doi:  10.1016/j.lungcan.2009.03.013 [DOI] [PubMed] [Google Scholar]
  7. Bonne-Andrea C., Tillier F., McShan G. D., Wilson V. G., Clertant P. (1997). Bovine papillomavirus type 1 DNA replication: the transcriptional activator E2 acts in vitro as a specificity factor. J. Virol. 71 (9), 6805–6815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Brooks G. F., Carroll K. C., Butel J. S., Morse S. A., Mietzner T. A. (2013). Medical Microbiology (United States: McGraw-Hill Education; ). [Google Scholar]
  9. Burd E. M. (2003). Human papillomavirus and cervical cancer. Clin. Microbiol. Rev. 16 (1), 1–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Burke J. R., Hura G. L., Rubin S. M. (2012). Structures of inactive retinoblastoma protein reveal multiple mechanisms for cell cycle control. Genes Dev. 26 (11), 1156–1166. doi:  10.1101/gad.189837.112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Burke J. R., Liban T. J., Restrepo T., Lee H. W., Rubin S. M. (2014). Multiple mechanisms for E2F binding inhibition by phosphorylation of the retinoblastoma protein c-terminal domain. J. Mol. Biol. 426 (1), 245–255. doi:  10.1016/j.jmb.2013.09.031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Castillo A., Wang L., Koriyama C., Eizuru Y., Jordan K., Akiba S. (2014). A systems biology analysis of the changes in gene expression via silencing of HPV-18 E1 expression in HeLa cells. Open Biol. 4 (10), 1-9. doi:  10.1098/rsob.130119 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Castro-Muñoz L. J., Manzo-Merino J., Muñoz-Bello J. O., Olmedo-Nieva L., Cedro-Tanda A., Alfaro-Ruiz L. A., et al. (2019). The human papillomavirus (HPV) E1 protein regulates the expression of cellular genes involved in immune response. Sci. Rep. 9 (1), 13620. doi:  10.1038/s41598-019-49886-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Chaiwongkot A., Vinokurova S., Pientong C., Ekalaksananan T., Kongyingyoes B., Kleebkaow P., et al. (2013). Differential methylation of E2 binding sites in episomal and integrated HPV 16 genomes in preinvasive and invasive cervical lesions. Int. J. Cancer 132 (9), 2087–2094. doi:  10.1002/ijc.27906 [DOI] [PubMed] [Google Scholar]
  15. Chan C. K., Aimagambetova G., Ukybassova T., Kongrtay K., Azizan A. (2019). Human papillomavirus infection and cervical cancer: Epidemiology, screening, and vaccination-review of current perspectives. J. Oncol. 2019, 3257939. doi:  10.1155/2019/3257939 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Chojnacki M., Melendy T. (2018). The human papillomavirus DNA helicase E1 binds, stimulates, and confers processivity to cellular DNA polymerase epsilon. Nucleic Acids Res. 46 (1), 229–241. doi:  10.1093/nar/gkx1103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Crook T., Tidy J. A., Vousden K. H. (1991). Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67 (3), 547–556. doi:  10.1016/0092-8674(91)90529-8 [DOI] [PubMed] [Google Scholar]
  18. Doorbar J., Medcalf E., Napthine S. (1996). Analysis of HPV1 E4 complexes and their association with keratins in vivo . Virology 218 (1), 114–126. doi:  10.1006/viro.1996.0171 [DOI] [PubMed] [Google Scholar]
  19. Enemark E. J., Joshua-Tor L. (2006). Mechanism of DNA translocation in a replicative hexameric helicase. Nature 442 (7100), 270–275. doi:  10.1038/nature04943 [DOI] [PubMed] [Google Scholar]
  20. Filippova M., Song H., Connolly J. L., Dermody T. S., Duerksen-Hughes P. J. (2002). The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J. Biol. Chem. 277 (24), 21730–21739. doi:  10.1074/jbc.M200113200 [DOI] [PubMed] [Google Scholar]
  21. Fradet-Turcotte A., Bergeron-Labrecque F., Moody C. A., Lehoux M., Laimins L. A., Archambault J. (2011). Nuclear accumulation of the papillomavirus E1 helicase blocks s-phase progression and triggers an ATM-dependent DNA damage response. J. Virol. 85 (17), 8996–9012. doi:  10.1128/JVI.00542-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Frattini M. G., Laimins L. A. (1994). Binding of the human papillomavirus E1 origin-recognition protein is regulated through complex formation with the E2 enhancer-binding protein. Proc. Natl. Acad. Sci. U.S.A. 91 (26), 12398–12402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ganguly N. (2012). Human papillomavirus-16 E5 protein: oncogenic role and therapeutic value. Cell Oncol. (Dordr) 35 (2), 67–76. doi:  10.1007/s13402-011-0069-x [DOI] [PubMed] [Google Scholar]
  24. German J. (1997). Bloom's syndrome. XX. the first 100 cancers. Cancer Genet. Cytogenet. 93 (1), 100–106. [DOI] [PubMed] [Google Scholar]
  25. Ghittoni R., Accardi R., Chiocca S., Tommasino M. (2015). Role of human papillomaviruses in carcinogenesis. Ecancermedicalscience 9, 526. doi:  10.3332/ecancer.2015.526 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Graham S. V. (2017). Keratinocyte differentiation-dependent human papillomavirus gene regulation. Viruses 9 (9), 1-18. doi:  10.3390/v9090245 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Hanahan D., Weinberg R. A. (2000). The hallmarks of cancer. Cell 100 (1), 57–70. doi:  10.1016/s0092-8674(00)81683-9 [DOI] [PubMed] [Google Scholar]
  28. Hanahan D., Weinberg R. A. (2011). Hallmarks of cancer: the next generation. Cell 144 (5), 646–674. doi:  10.1016/j.cell.2011.02.013 [DOI] [PubMed] [Google Scholar]
  29. Hirose Y., Yamaguchi-Naka M., Onuki M., Tenjimbayashi Y., Tasaka N., Satoh T., et al. (2020). High levels of within-host variations of human papillomavirus 16 E1/E2 genes in invasive cervical cancer. Front. Microbiol. 11. doi:  10.3389/fmicb.2020.596334 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Hughes F. J., Romanos M. A. (1993). E1 protein of human papillomavirus is a DNA helicase/ATPase. Nucleic Acids Res. 21 (25), 5817–5823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Ichim G., Tait S. W. (2016). A fate worse than death: apoptosis as an oncogenic process. Nat. Rev. Cancer 16 (8), 539–548. doi:  10.1038/nrc.2016.58 [DOI] [PubMed] [Google Scholar]
  32. Ishii Y., Taguchi A., Kukimoto I. (2020). The homeobox transcription factor HOXC13 upregulates human papillomavirus E1 gene expression and contributes to viral genome maintenance. FEBS Lett. 594 (4), 751–762. doi:  10.1002/1873-3468.13646 [DOI] [PubMed] [Google Scholar]
  33. Jeon S., Allen-Hoffmann B. L., Lambert P. F. (1995). Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 69 (5), 2989–2997. doi:  10.1128/JVI.69.5.2989-2997.1995 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Joha S., Nugues A. L., Hetuin D., Berthon C., Dezitter X., Dauphin V., et al. (2012). GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells. Oncogene 31 (11), 1419–1430. doi:  10.1038/onc.2011.328 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Kelley M. L., Keiger K. E., Lee C. J., Huibregtse J. M. (2005). The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. J. Virol. 79 (6), 3737–3747. doi:  10.1128/JVI.79.6.3737-3747.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. King L. E., Fisk J. C., Dornan E. S., Donaldson M. M., Melendy T., Morgan I. M. (2010). Human papillomavirus E1 and E2 mediated DNA replication is not arrested by DNA damage signalling. Virology 406 (1), 95–102. doi:  10.1016/j.virol.2010.06.033 [DOI] [PubMed] [Google Scholar]
  37. Langie S. A., Koppen G., Desaulniers D., Al-Mulla F., Al-Temaimi R., Amedei A., et al. (2015). Causes of genome instability: the effect of low dose chemical exposures in modern society. Carcinogenesis 36 Suppl 1, S61–S88. doi:  10.1093/carcin/bgv031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Longworth M. S., Laimins L. A. (2004). Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol. Mol. Biol. Rev. 68 (2), 362–372. doi:  10.1128/MMBR.68.2.362-372.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Loo Y. M., Melendy T. (2004). Recruitment of replication protein a by the papillomavirus E1 protein and modulation by single-stranded DNA. J. Virol. 78 (4), 1605–1615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Mantovani F., Banks L. (2001). The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20 (54), 7874–7887. doi:  10.1038/sj.onc.1204869 [DOI] [PubMed] [Google Scholar]
  41. Martin G. M. (1985). Genetics and aging; the Werner syndrome as a segmental progeroid syndrome. Adv. Exp. Med. Biol. 190, 161–170. [DOI] [PubMed] [Google Scholar]
  42. Masoud G. N., Li W. (2015). HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm. Sin. B 5 (5), 378–389. doi:  10.1016/j.apsb.2015.05.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. McBride A. A. (2017). Oncogenic human papillomaviruses. Philos. Trans. R Soc. Lond. B Biol. Sci. 372 (1732), 1-9. doi:  10.1098/rstb.2016.0273 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Moody C. A., Laimins L. A. (2009). Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation. PloS Pathog. 5 (10), e1000605. doi:  10.1371/journal.ppat.1000605 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Moody C. A., Laimins L. A. (2010). Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 10 (8), 550–560. doi:  10.1038/nrc2886 [DOI] [PubMed] [Google Scholar]
  46. Munger K., Scheffner M., Huibregtse J. M., Howley P. M. (1992). Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv. 12, 197–217. [PubMed] [Google Scholar]
  47. Negrini S., Gorgoulis V. G., Halazonetis T. D. (2010). Genomic instability–an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11 (3), 220–228. doi:  10.1038/nrm2858 [DOI] [PubMed] [Google Scholar]
  48. Nguyen M., Song S., Liem A., Androphy E., Liu Y., Lambert P. F. (2002). A mutant of human papillomavirus type 16 E6 deficient in binding alpha-helix partners displays reduced oncogenic potential in vivo . J. Virol. 76 (24), 13039–13048. doi:  10.1128/jvi.76.24.13039-13048.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Petry K. U. (2014). HPV and cervical cancer. Scand. J. Clin. Lab. Invest. Suppl. 244, 59–62. doi:  10.3109/00365513.2014.936683 [DOI] [PubMed] [Google Scholar]
  50. Pirami L., Giache V., Becciolini A. (1997). Analysis of HPV16, 18, 31, and 35 DNA in pre-invasive and invasive lesions of the uterine cervix. J. Clin. Pathol. 50 (7), 600–604. doi:  10.1136/jcp.50.7.600 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Plummer M., Schiffman M., Castle P. E., Maucort-Boulch D., Wheeler C. M., Group A. (2007). A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J. Infect. Dis. 195 (11), 1582–1589. doi:  10.1086/516784 [DOI] [PubMed] [Google Scholar]
  52. Porter S. S., Stepp W. H., Stamos J. D., McBride A. A. (2017). Host cell restriction factors that limit transcription and replication of human papillomavirus. Virus Res. 231, 10–20. doi:  10.1016/j.virusres.2016.11.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Reinson T., Toots M., Kadaja M., Pipitch R., Allik M., Ustav E., et al. (2013). Engagement of the ATR-dependent DNA damage response at the human papillomavirus 18 replication centers during the initial amplification. J. Virol. 87 (2), 951–964. doi:  10.1128/JVI.01943-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Sabol I., Matovina M., Gasperov N. M., Grce M. (2008). Identification of a novel human papillomavirus type 16 E1 gene variant with potentially reduced oncogenicity. J. Med. Virol. 80 (12), 2134–2140. doi:  10.1002/jmv.21304 [DOI] [PubMed] [Google Scholar]
  55. Sakakibara N., Mitra R., McBride A. A. (2011). The papillomavirus E1 helicase activates a cellular DNA damage response in viral replication foci. J. Virol. 85 (17), 8981–8995. doi:  10.1128/JVI.00541-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Schiffman M., Castle P. E., Jeronimo J., Rodriguez A. C., Wacholder S. (2007). Human papillomavirus and cervical cancer. Lancet 370 (9590), 890–907. doi:  10.1016/S0140-6736(07)61416-0 [DOI] [PubMed] [Google Scholar]
  57. Schmitt M., Dalstein V., Waterboer T., Clavel C., Gissmann L., Pawlita M. (2011). The HPV16 transcriptome in cervical lesions of different grades. Mol. Cell Probes 25 (5-6), 260–265. doi:  10.1016/j.mcp.2011.05.003 [DOI] [PubMed] [Google Scholar]
  58. Seth R. B., Sun L., Chen Z. J. (2006). Antiviral innate immunity pathways. Cell Res. 16 (2), 141–147. doi:  10.1038/sj.cr.7310019 [DOI] [PubMed] [Google Scholar]
  59. Shiota M., Song Y., Yokomizo A., Kiyoshima K., Tada Y., Uchino H., et al. (2010). Foxo3a suppression of urothelial cancer invasiveness through Twist1, y-box-binding protein 1, and e-cadherin regulation. Clin. Cancer Res. 16 (23), 5654–5663. doi:  10.1158/1078-0432.CCR-10-0376 [DOI] [PubMed] [Google Scholar]
  60. Shou Z., Lin L., Liang J., Li J. L., Chen H. Y. (2012). Expression and prognosis of FOXO3a and HIF-1alpha in nasopharyngeal carcinoma. J. Cancer Res. Clin. Oncol. 138 (4), 585–593. doi:  10.1007/s00432-011-1125-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Wang-Johanning F., Lu D. W., Wang Y., Johnson M. R., Johanning G. L. (2002). Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep papanicolaou tests using real-time polymerase chain reaction analysis. Cancer 94 (8), 2199–2210. doi:  10.1002/cncr.10439 [DOI] [PubMed] [Google Scholar]
  62. Watanabe S., Watanabe K., Akimov V., Bartkova J., Blagoev B., Lukas J., et al. (2013). JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1-mediated chromatin response to DNA breaks. Nat. Struct. Mol. Biol. 20 (12), 1425–1433. doi:  10.1038/nsmb.2702 [DOI] [PubMed] [Google Scholar]
  63. Waxman A. G., Chelmow D., Darragh T. M., Lawson H., Moscicki A. B. (2012). Revised terminology for cervical histopathology and its implications for management of high-grade squamous intraepithelial lesions of the cervix. Obstet. Gynecol. 120 (6), 1465–1471. doi:  10.1097/AOG.0b013e31827001d5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Williams V. M., Filippova M., Soto U., Duerksen-Hughes P. J. (2011). HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress. Future Virol. 6 (1), 45–57. doi:  10.2217/fvl.10.73 [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Xia Y., Shen S., Verma I. M. (2014). NF-κB, an active player in human cancers. Cancer Immunol. Res. 2 (9), 823–830. doi:  10.1158/2326-6066.Cir-14-0112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Yao Y., Yan Z., Dai S., Li C., Yang L., Liu S., et al. (2019). Human papillomavirus type 16 E1 mutations associated with cervical cancer in a han Chinese population. Int. J. Med. Sci. 16 (7), 1042–1049. doi:  10.7150/ijms.34279 [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Yousefi Z., Aria H., Ghaedrahmati F., Bakhtiari T., Azizi M., Bastan R., et al. (2021). An update on human papilloma virus vaccines: History, types, protection, and efficacy. Front. Immunol. 12. doi:  10.3389/fimmu.2021.805695 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Cellular and Infection Microbiology are provided here courtesy of Frontiers Media SA

RESOURCES